Please assess the completion status of the following clinical trial:

Trial Title: Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females aged ≥18 years~2. Congestive Heart Failure (CHF) New York Heart Association (NYHA) class II-IV with 25%≤ Left Ventricular Ejection Fraction (LVEF) ≤40% (ECHO within last 6 months)~   * NT-proBNP ≥ 600 pg/mL OR~  * NT-proBNP ≥ 400 pg/mL and a hospitalization for heart failure within the last 12 months~3. Stable and optimized on an angiotensin-converting-enzyme inhibitor (ACEI) equivalent to enalapril ≥ 10 twice a day (BID) for at least 4 weeks~4. Stable and optimized on a beta-blocker for at least 4 weeks~5. Optimized dosing of aldosterone antagonist at stable dose for at least 4 weeks~Exclusion Criteria:~1. History of angioedema~2. estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m2 at screening~3. Serum potassium \> 5.2 mmol/L at screening~4. Symptomatic hypotension as defined by Investigator, systolic blood pressure (SBP) \< 100 mmHg at screening~5. Current acute decompensated heart failure~6. History of severe pulmonary disease~7. Active malignancy~8. Requirement for treatment with both angiotensin-converting-enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label Entresto (Type: OTHER): All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).